Simplify Logo

Full-Time

Medical Director/Senior Medical Director

Confirmed live in the last 24 hours

Voyager Therapeutics

Voyager Therapeutics

51-200 employees

Develops genetic medicines for neurological diseases

Biotechnology
Healthcare

Mid, Senior

Lexington, MA, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Communications
Data Analysis
Requirements
  • M.D. with deep Neuroscience experience
  • 3+ years’ experience in clinical development within a biotech or pharmaceutical company
  • Experience in neurology clinical development is required and experience in neuromuscular diseases and/or dementia is optimal
  • Experience in gene therapy drug development, RNA, nucleotide, and/or gene editing experience considered a plus
  • Experience working collaboratively within a multi-disciplinary team of colleagues and proven ability to interact with external experts and investigators
  • Adaptability, flexibility, independence, and resourcefulness to roll-up-sleeves and multi-task to thrive in a small company
  • Experience in early-stage development programs
  • Demonstrated command working with FDA, MHRA and ICH GCP guidelines to ensure the appropriate conduct of clinical studies
  • Effective oral and written communication skills are required, as are excellent interpersonal skills with demonstrated ability to work with a small growing team. Marked proficiency in clinical/medical writing
  • Integrity, honesty and highest ethical standards and a sense of personal accountability
Responsibilities
  • Contribute to the development and execution of comprehensive clinical development plans for Voyager’s development programs. Offer expert clinical advice, drawing on extensive clinical knowledge. Provide feedback on clinical study data, reports, protocols, and development plans. Collaborate with early development research teams on clinical aspects and disease indications
  • Serve as a medical expert in the company, staying current with the latest research and medical advancements in the fields being studied
  • Contribute to the design and oversight of clinical trials, develop study protocols, case report forms, and informed consent documents, ensuring they are conducted in compliance with regulatory standards and ethical guidelines
  • Collaborate with the regulatory team to prepare and submit regulatory documents to health authorities, including INDs, NDAs, and BLAs. Collaborate with study team to prepare and complete clinical study reports, investigator’s brochures
  • Provide medical oversight for future clinical trials, including safety monitoring, data analysis, and interpretation of clinical trial results
  • Build and maintain strong relationships with key opinion leaders (KOLs) and academic institutions to support the company's scientific and clinical objectives
  • Collaborate closely with other departments such as clinical operations, technical operations/CMC, translational research and regulatory affairs to ensure alignment on program objectives
  • Lead the development of scientific publications, presentations, and educational materials related to Voyager’s programs

Voyager Therapeutics develops genetic medicines aimed at treating neurological diseases, particularly those affecting the central nervous system like amyotrophic lateral sclerosis (ALS). Their approach involves using a proprietary platform that utilizes adeno-associated virus (AAV) technology to deliver genetic material directly to the brain through intravenous dosing, overcoming the challenge of the blood-brain barrier. Unlike many competitors, Voyager focuses on creating treatments that are specifically designed for neurological conditions, and they emphasize collaboration with larger pharmaceutical companies to enhance their research and development efforts. The company's goal is to provide transformative therapies that significantly improve the lives of patients suffering from severe neurological disorders.

Company Stage

IPO

Total Funding

$344M

Headquarters

Cambridge, Massachusetts

Founded

2014

Growth & Insights
Headcount

6 month growth

0%

1 year growth

8%

2 year growth

48%
Simplify Jobs

Simplify's Take

What believers are saying

  • Voyager's recent $100 million upfront payment from Novartis highlights strong financial backing and potential for rapid growth.
  • The appointment of experienced executives like Nathan Jorgensen as CFO and Toby Ferguson as CMO strengthens the company's leadership team.
  • The selection of a development candidate for the GBA1 program in collaboration with Neurocrine Biosciences demonstrates the productivity and potential of their partnerships.

What critics are saying

  • The highly specialized focus on neurological diseases may limit market opportunities compared to broader biotech firms.
  • Dependence on partnerships and milestone payments introduces financial uncertainty if collaborations do not yield expected results.

What makes Voyager Therapeutics unique

  • Voyager Therapeutics leverages its proprietary AAV capsid discovery platform to deliver genetic material directly to the brain, a significant advancement over traditional methods.
  • The company's focus on crossing the blood-brain barrier addresses a critical challenge in treating neurological diseases, setting it apart from many competitors.
  • Voyager's strong emphasis on collaborative partnerships with major pharmaceutical companies like Novartis accelerates its R&D and commercialization efforts.